GSK Confirms Arexvy Price And US Contract Negotiations Ahead Of Launch
Talks Crucial To Launch Success
Executive Summary
GSK is gearing up for its most important new product launch in years and hopes US payers will buy into Arexvy’s likely higher price than Pfizer’s rival RSV vaccine.
You may also be interested in...
Stock Watch: Johnson & Johnson’s Q2 Helps Pharma Sentiment
Pharmaceutical stocks have underperformed in the year to date, but J&J, Novartis and GSK may have started to turn the worm.
Quick Listen: Scrip's Five Must-Know Things
In this week's episode of Five Must-Know Things: large M&A deals under regulatory review; surprise at Roche’s cardiovascular deal; BioNTech’s multiple China partnerships; GSK preps for US RSV vaccine launch; and a look at the dynamic multiple myeloma market.
GSK And Pfizer RSV Vaccines Get US Recommendation – But Big Decisions On Pricing Yet To Come
GSK and Pfizer have both raised their price ranges based on longer-term efficacy data for their RSV vaccines, but Pfizer may choose to undercut on price in order to win market share against its rival’s more favorable data.